Table: Daito - 9-MTH group results
Apr 12 (Reuters)-
Daito Pharamaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Feb 28, 2019 Feb 28, 2018 May 31, 2019
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 30.40 29.64 40.80
(+2.6 pct) (+6.2 pct) (+2.3 pct)
Operating 3.67 3.19 4.30
(+15.1 pct) (+3.6 pct) (+3.3 pct)
Recurring 3.75 3.25 4.35
(+15.6 pct) (+6.7 pct) (+2.5 pct)
Net 2.55 2.30 3.10
(+10.9 pct) (+12.6 pct) (+1.9 pct)
EPS 203.81 yen 183.81 yen 247.72 yen
Ann Div 33.00 yen 36.00 yen
-Q2 div 18.00 yen 15.00 yen
-Q4 div 18.00 yen 18.00 yen
NOTE - Daito Pharamaceutical Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4577.T
Recent news on Daito Pharmaceutical
See all newsTo Buy Back Up To 4.4% Of Own Shares Worth 2 Billion Yen
Table: Daito Pharmaceutical -Q1 group results
Execution Of JV And Share Transfer Agreement For Transfer Of Kyorin Pharmaceutical's Generic Drug Business To JV By Daito, Meiji Seika Pharma And Dbj
Table: Daito -2025/26 parent results
Table: Daito -2025/26 group results